1. Gupta RK, Topol EJ. COVID-19 vaccine breakthrough infections.Science. 2021;374(6575):1561-1562.
2. Maclean P, Mentzer AJ, Lambe T, Knight J. Why do breakthroughCOVID-19 infections occur in the vaccinated?. QJM. 2022;115(2):67-68.
3. Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impacton patients with COVID-19. SN Comprehensive Clinical Medicine.2020;2(8):1069-1076.
4. Guan W-j, Liang W-h, Zhao Y, et al. Comorbidity and its impacton 1590 patients with COVID-19 in China: a nationwide analysis.European Respiratory Journal. 2020;55(5)
5. Verma A, Kumar I, Singh PK, et al. Initial comparative analysisof pulmonary involvement on HRCT between vaccinated andnon-vaccinated subjects of COVID-19. European Radiology.2022;32(6):4275-4283.
6. Hitchings MD, Ranzani OT, Torres MSS, et al. Effectiveness ofCoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study. The Lancet Regional Health-Americas.2021;1:100025.
7. Bernal JL, Andrews N, Gower C, et al. Early effectiveness of COVID-19vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirusvector vaccine on symptomatic disease, hospitalisations and mortalityin older adults in England. MedRxiv. 2021. 2021-2023
8. Naik BR, Kumar SA, Rachegowda N, Ullas LY, Revanth R, Aluru NRVS.Severity of COVID-19 Infection Using Chest Computed TomographySeverity Score Index Among Vaccinated and Unvaccinated COVID-19-Positive Healthcare Workers: An Analytical Cross-Sectional Study.Cureus. 2022;14(2):e22087
9. Fatima S, Zafar A, Afzal H, et al. COVID-19 infection amongvaccinated and unvaccinated: Does it make any difference? PLoS One.2022;17(7): e0270485.
10. Pan F, Ye T, Sun P, et al. Time course of lung changes on chest CTduring recovery from 2019 novel coronavirus (COVID-19) pneumonia.Radiology. 295.3: 715-721.
11. Collier DA, Ferreira IATM, Kotagiri P, et al. Age-related immuneresponse heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature.2021;596(7872):417-422.
12. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety andimmunogenicity of ChAdOx1 nCoV-19 vaccine administeredin a prime-boost regimen in young and old adults (COV002): asingle-blind, randomised, controlled, phase 2/3 trial. The Lancet.2020;396(10267):1979-1993.
13. Goronzy JJ, Weyand CM. Understanding immunosenescence toimprove responses to vaccines. Nature immunology. 2013;14(5):428-436.
14. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants—clinical,public health, and vaccine implications. New England Journal ofMedicine. 2021;384(19):1866-1868.